Showing results (101-110 of 162) with videos related to

Sort By:
Pageof 17
Journal of Experimental & Clinical Cancer Research : CR|October 18, 2015
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitroFrancesca Ferrari, Stefania Bellone, Jonathan Black, et al.
BMC Cancer|June 23, 2011
Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factorEmiliano Cocco, Joyce Varughese, Natalia Buza, et al.
Gynecologic Oncology|May 4, 2024
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomasCem Demirkiran, Michelle Greenman, Stefania Bellone, et al.
Gynecologic Oncology|March 16, 2024
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancerBlair McNamara, Cem Demirkiran, Tobias Max Philipp Hartwich, et al.
British Journal of Cancer|September 2, 2015
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomasJonathan D Black, Salvatore Lopez, Emiliano Cocco, et al.
Cancer Medicine|June 4, 2014
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.
Molecular Cancer Therapeutics|September 4, 2015
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In VivoSalvatore Lopez, Emiliano Cocco, Jonathan Black, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 15, 2011
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibodyRhoda Raji, Federica Guzzo, Luisa Carrara, et al.
Cancer|September 25, 2014
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.
Gynecologic Oncology|August 12, 2015
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivoCarlton L Schwab, Diana P English, Jonathan Black, et al.
Pageof 17